Sponsored Links
| Abbott Reports Interim Results From Phase III Open-Label Study Of Investigational Treatment For Advanced Parkinson's Disease |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias... Read more: Clinical Trials / Drug Trials News From Medical News Today
|